ࡗ ࡗPurpose: To report the 6-month angiographic results from a prospective single-center study investigating the efficacy and outcome of sirolimus-eluting stents used for bailout after infrapopliteal revascularization of patients with critical limb ischemia (CLI Results: Hyperlipidemia and symptomatic cardiac and carotid diseases were more pronounced in group S (pϽ0.05). Technical success was 96.6% (28/29 limbs) in group B versus 100.0% in group S (pϭ0.16). Six-month primary patency was 68.1% in group B versus 92.0% in group S (pϽ0.002). Binary in-stent and in-segment restenosis rates were 55.3% and 66.0%, respectively, in patients with bare stents versus 4.0% and 32.0%, respectively, in patients treated with the sirolimus-eluting stents (both pϽ0.001). The target lesion reintervention rate at 6 months was 17.0% in group B versus 4.0% in group S (pϭ0.02). Limb salvage was 100% in both groups. Six-month mortality and minor amputation rates were 6.9% and 17.2%, respectively, in group B versus 10.3% and 3.4%, respectively, in group S (pϭ0.32 and pϭ0.04, respectively). Conclusions: Sirolimus-eluting stents seem to restrict neointimal hyperplasia in the infrapopliteal vascular bed. J Endovasc Ther 2005;12:685-695